Weiss Ratings Reiterates Hold (C) Rating for Bausch Health Cos (NYSE:BHC)

Key Points

• Weiss Ratings has reaffirmed a "Hold (C)" rating for Bausch Health Cos (NYSE:BHC), while Wall Street Zen downgraded it from "Strong Buy" to "Buy." This reflects a cautious outlook on the stock's performance.
• Bausch Health's stock traded down by 3.1% to $6.19, with a market cap of $2.29 billion and a price-to-earnings ratio of 23.79.
• Insider activity has increased, with Director John Paulson acquiring over 34 million shares, raising their stake to nearly 70.8 million shares, indicating significant confidence in the company's future.

Bausch Health Cos (NYSE:BHC - Get Free Report)'s stock had its "hold (c)" rating reaffirmed by equities research analysts at Weiss Ratings in a research note issued to investors on Friday,Weiss Ratings reports.

Separately, Wall Street Zen cut shares of Bausch Health Cos from a "strong-buy" rating to a "buy" rating in a report on Saturday, October 11th. Three equities research analysts have rated the stock with a Hold rating, According to MarketBeat.com, Bausch Health Cos has an average rating of "Hold" and an average target price of $9.00.

Bausch Health Cos Trading Down 3.1%

Shares of Bausch Health Cos stock traded down $0.20 on Friday, hitting $6.19. The stock had a trading volume of 3,479,724 shares, compared to its average volume of 2,499,763. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 141.90. Bausch Health Cos has a one year low of $4.25 and a one year high of $9.85. The stock has a market cap of $2.29 billion, a price-to-earnings ratio of 23.79 and a beta of 0.43. The stock's 50-day simple moving average is $6.88 and its two-hundred day simple moving average is $6.03.

Bausch Health Cos (NYSE:BHC - Get Free Report) last issued its earnings results on Wednesday, July 30th. The company reported $0.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.97 by ($0.07). Bausch Health Cos had a negative return on equity of 852.36% and a net margin of 0.99%.The firm had revenue of $2.57 billion during the quarter, compared to the consensus estimate of $2.47 billion. Bausch Health Cos has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Bausch Health Cos will post 4.41 EPS for the current year.

Insider Activity at Bausch Health Cos

In other Bausch Health Cos news, Director John Paulson bought 34,721,118 shares of the company's stock in a transaction dated Thursday, August 14th. The shares were purchased at an average price of $9.00 per share, for a total transaction of $312,490,062.00. Following the acquisition, the director owned 70,755,869 shares in the company, valued at approximately $636,802,821. This represents a 96.35% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. In the last quarter, insiders have acquired 37,964,167 shares of company stock worth $333,757,793. Insiders own 19.97% of the company's stock.

Institutional Trading of Bausch Health Cos

Hedge funds have recently modified their holdings of the business. Cary Street Partners Financial LLC bought a new stake in shares of Bausch Health Cos during the 1st quarter valued at $27,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Bausch Health Cos in the 1st quarter worth about $27,000. SBI Securities Co. Ltd. raised its position in shares of Bausch Health Cos by 244.2% in the 1st quarter. SBI Securities Co. Ltd. now owns 4,230 shares of the company's stock worth $27,000 after purchasing an additional 3,001 shares during the last quarter. Russell Investments Group Ltd. raised its position in shares of Bausch Health Cos by 65.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company's stock worth $51,000 after purchasing an additional 3,106 shares during the last quarter. Finally, Wealthquest Corp purchased a new position in Bausch Health Cos in the 1st quarter worth about $58,000. Institutional investors own 78.65% of the company's stock.

Bausch Health Cos Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.